BCAB BioAtla
- 1.450
- +0.060+4.32%
BioAtla News
BioAtla (BCAB) Receives a Buy From J.P. Morgan
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
Buy Rating for BioAtla: Promising Clinical Assets and Undervaluation Present Investment Opportunity
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Robust Financials
BioAtla Analyst Ratings
Buy Rating for BioAtla: Promising Clinical Data and Strong Financial Position Signal Upside Potential
BioAtla Analyst Ratings
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Strategic Pipeline Progress
Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability
BioAtla Analyst Ratings
BioAtla Analyst Ratings
Buy Rating for BioAtla Amid Robust Pipeline and Encouraging Clinical Trials
Strong Buy Rating for BioAtla Reflects Potential of BA3071 and Promising Clinical Results
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
BioAtla Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Gamida Cell (GMDA) and Sagimet Biosciences, Inc. Class A (SGMT)
Strong Buy Rating for BioAtla Amid BA3011's Promising Efficacy and Strategic FDA Engagement
Promising Investment Prospects in BioAtla Backed by Strong Phase 2 Assets and Financial Stability: A Buy Rating Recommendation
Analysts Offer Insights on Healthcare Companies: BioAtla (BCAB) and Silk Road Medical (SILK)
Analysts Conflicted on These Healthcare Names: BioAtla (BCAB), Lyra Therapeutics (LYRA) and Apollo Medical Holdings (AMEH)
Analysis
Price Target
No Data
